Back Login to subscribe 🔔 Set Alert

MNOV Medicinova Inc Common Stock

Sector: Healthcare
Industry: Biotechnology
15 min delay
Today's News Sentiment
Loading...
Upcoming Earnings
Loading...
MNOV Fundamental Data
Loading...
Similar Companies
Loading...
MNOV Options Chain
Put/Call Ratio
-
-
Expected Move
-
-
Max Pain
-
-
ATM Call Break-even
-
-
ATM Put Break-even
-
-
Loading options…
CALLS
Strike Last Bid Ask Mark IV Volume OI Δ Delta Θ Theta
PUTS
Strike Last Bid Ask Mark IV Volume OI Δ Delta Θ Theta
MNOV Insider Transactions
Loading insider data…
MNOV News
Date Headline Sentiment
MediciNova Provides Update On Recent Topline Results Of Its Phase 2 Clinical Trial Evaluating MN-001 For Treatment Of Nonalcoholic Fatty Liver Disease And Hypertriglyceridemia Associated With Type 2 Diabetes Mellitus; At End Of The 24-Week Period, Serum Triglycerides, Liver Fat, And Body Weight Were Also Reduced In The MN-001 Group Compared With Placebo, Although These Differences Did Not Reach Statistical Significance
85.84%
12 Health Care Stocks Moving In Monday's Intraday Session
96.55%
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles
96.27%
MediciNova shares are trading lower after the company announced the topline results from MN-001-NATG-202, a Phase 2 clinical trial evaluating MN-001 for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease associated with type 2 diabetes mellitus.
96.25%
12 Health Care Stocks Moving In Monday's Pre-Market Session
96.41%
MediciNova Announces Topline Results From MN-001-NATG-202, Its Phase 2 Clinical Trial Evaluating MN-001 (Tipelukast) For Treatment Of Hypertriglyceridemia And Nonalcoholic Fatty Liver Disease Associated With Type 2 Diabetes Mellitus; At Week 24, The MN-001 Group Continued To Show A Numerical Reduction From Baseline Value, Although The Difference Between The MN-001 And Placebo Groups Were Not Statistically Significant
92.78%
MediciNova Completes Last Patient, Last Visit In The Double-Blind Portion Of COMBAT-ALS Phase 2B/3 Clinical Trial Evaluating MN-166 For The Treatment Of Amyotrophic Lateral Sclerosis
58.55%
12 Health Care Stocks Moving In Thursday's Intraday Session
96.37%
MediciNova shares are trading higher after Roth Capital initiated coverage on the stock with a Buy rating and announced a $6 price target.
94.54%
Roth Capital Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $6
59.16%